The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study (STARTING-2)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01716481|
Recruitment Status : Recruiting
First Posted : October 29, 2012
Last Update Posted : April 26, 2017
Samsung Medical Center
Pharmicell Co., Ltd.
Information provided by (Responsible Party):
Oh Young Bang, Samsung Medical Center
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Kim SJ, Moon GJ, Chang WH, Kim YH, Bang OY; STARTING-2 (STem cell Application Researches and Trials In NeuroloGy-2) collaborators. Intravenous transplantation of mesenchymal stem cells preconditioned with early phase stroke serum: current evidence and study protocol for a randomized trial. Trials. 2013 Oct 1;14:317. doi: 10.1186/1745-6215-14-317.